MedTrace Logo

Extension Study of Participants From SPG302-ALS-001

NCT06903286 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-12-17

No results posted yet for this study

Summary

This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

SPG302

Open label SPG302 to be self-administered daily by eligible participants for 52 weeks.

Sponsors & Collaborators

  • Spinogenix

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-29
Primary Completion
2025-06-30
Completion
2025-08-31
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06903286 on ClinicalTrials.gov